Otros idiomas IntelGenx Technologies Corp. Toronto S.E.

Acciones

IGX

US45822R1014

Precio de cierre Toronto S.E. Otros sitios de cotización 00:00:00 18/10/2021			Varia. Cinco días.	Varia. 1 de enero.
0,78 ^CAD	+9,86 %		+50,00 %	+173,68 %

08/04	Intelgenx anuncia que se ha administrado Montelukast Versafilm® a los primeros pacientes con enfermedad de Parkinson en el ensayo clínico de fase 2 ?Montpark? Montpark	CI
05/04	IntelGenx actualiza el estado de su ANDA de película bucal de buprenorfina	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial	08/04
Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial	08/04
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	08/04
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	05/04
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	05/04
IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDA	05/04
IntelGenx Technologies Narrows Q4 Loss, Revenue Rises	21/03
IntelGenx Technologies Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results	21/03
IntelGenx Technologies : 25 10.42pm MOCK-UP with special characters / * $ % + ` ' ' `	15/03
IntelGenx Technologies : 26 10.45pm MOCK-UP with special characters / * $ % + ` ' ' `	15/03
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow	14/03
IntelGenx Subsidiary Signs Third Amended, Restated Loan Agreement With atai Life Sciences	11/03
IntelGenx Brief: Entering Into a Third Amended and Restated Loan Agreement With atai Life Sciences	11/03
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences	11/03
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences	11/03
IntelGenx Technologies Corp. announced that it expects to receive $2 million in funding	08/03
UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering	20/02
IntelGenx Brief: Launching Regulation A Offering of Up to 2 Million shares In Series A Convertible Cumulative Preferred Stock, Par Value $0.00001 Per Share, at an Offering Price of $10.00 Each, For a Max Offering amount of $20 Million	20/02
IntelGenx Technologies Corp. announced that it expects to receive $20 million in funding	14/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas IntelGenx Technologies Corp. Toronto S.E.

Acciones

IGX

US45822R1014

Otros idiomas

Filtros